Health Condition 1: B20- Human immunodeficiency virus [HIV]disease Health Condition 2: B348- Other viral infections of unspecified site
Conditions
Interventions
Intervention1: Not applicable: Not applicable
Control Intervention1: Not applicable: Not applicable
Sponsors
University of Oslo The Research Council of Norway
Eligibility
Inclusion criteria
Inclusion criteria: Population Clinical trials in literature related to HIV, Ebola, and COVID-19 conducted in Brazil, India, Kenya, Nepal, the Philippines, and Tanzania in the selected areas Intervention Clinical trials evaluating interventions for prevention, treatment, or management of HIV, Ebola, or COVID19 Outcomes Those studies that provide data on post-trial arrangements, nature of these arrangements, including participant follow up, and access to treatment, data sharing, community engagement Study designs Randomized controlled trials, observational studies, and qualitative studies. Any and all designs will be taken into consideration
Exclusion criteria
Exclusion criteria: Studies not related to HIV, Ebola, or COVID-19; Studies conducted outside the specified countries;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Available scientific and grey literature publications on PTA with regards to COVID-19 clinical trials, HIV and Ebola in LMICs Timepoint: 1 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Available government, relevant NGOs, and patient social media sites where policies or information on PTA has been posted and review comments from the publicTimepoint: 1 year;Available laws, regulations, policies, and norms on PTA in the 6 LMICs countriesTimepoint: 1 year;Available newspaper and social media articles in the past 10 years on PTA in the 5 LMICs countriesTimepoint: 1 year | — |
Countries
Brazil, India, Kenya, Nepal, Norway, Philippines, Tanzania
Contacts
Public ContactDr Vijaya Sandeep Gunjal
Seth GSMC and KEMH Mumbai
Outcome results
None listed